Prelude Capital Management, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

A detailed history of Prelude Capital Management, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 582 shares of REGN stock, worth $408,907. This represents 0.04% of its overall portfolio holdings.

Number of Shares
582
Previous 582 -0.0%
Holding current value
$408,907
Previous $611,000 -0.0%
% of portfolio
0.04%
Previous 0.02%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$1024.09 - $1201.76 $596,020 - $699,424
582 New
582 $611,000
Q2 2023

Aug 14, 2023
BUY
$700.03 - $830.35 $140,706 - $166,900
201 Added 40.94%
692 $497,000
Q1 2023

May 15, 2023
BUY
$680.49 - $826.97 $334,120 - $406,042
491 New
491 $403,000
Q1 2022

May 16, 2022
SELL
$595.12 - $698.43 $681,412 - $799,702
-1,145 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$543.48 - $670.97 $175,544 - $216,723
323 Added 39.29%
1,145 $723,000
Q3 2021

Nov 15, 2021
SELL
$574.03 - $680.96 $668,170 - $792,637
-1,164 Reduced 58.61%
822 $497,000
Q2 2021

Aug 16, 2021
BUY
$472.8 - $558.54 $938,980 - $1.11 Million
1,986 New
1,986 $1.11 Million
Q1 2021

May 17, 2021
SELL
$446.73 - $548.2 $507,485 - $622,755
-1,136 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$478.3 - $607.98 $122,923 - $156,250
257 Added 29.24%
1,136 $549,000
Q3 2020

Nov 16, 2020
SELL
$544.75 - $658.21 $212,452 - $256,701
-390 Reduced 30.73%
879 $492,000
Q2 2020

Aug 14, 2020
BUY
$493.32 - $643.92 $557,944 - $728,273
1,131 Added 819.57%
1,269 $791,000
Q1 2020

May 15, 2020
SELL
$336.18 - $494.43 $749,345 - $1.1 Million
-2,229 Reduced 94.17%
138 $67,000
Q4 2019

Feb 14, 2020
BUY
$274.13 - $376.51 $635,981 - $873,503
2,320 Added 4936.17%
2,367 $889,000
Q3 2019

Nov 14, 2019
SELL
$273.46 - $318.39 $554,576 - $645,694
-2,028 Reduced 97.73%
47 $13,000
Q2 2019

Aug 14, 2019
BUY
$299.6 - $414.82 $462,282 - $640,067
1,543 Added 290.04%
2,075 $649,000
Q1 2019

May 15, 2019
SELL
$372.08 - $439.57 $446,868 - $527,923
-1,201 Reduced 69.3%
532 $218,000
Q4 2018

Feb 14, 2019
SELL
$335.82 - $403.04 $143,730 - $172,501
-428 Reduced 19.81%
1,733 $647,000
Q3 2018

Nov 14, 2018
BUY
$351.14 - $408.51 $116,929 - $136,033
333 Added 18.22%
2,161 $873,000
Q2 2018

Aug 14, 2018
BUY
$284.6 - $344.99 $520,248 - $630,641
1,828 New
1,828 $631,000
Q4 2017

Feb 14, 2018
SELL
$358.63 - $469.95 $580,263 - $760,379
-1,618 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$431.38 - $504.0 $697,972 - $815,472
1,618
1,618 $723,000

Others Institutions Holding REGN

# of Institutions
1,534
Shares Held
83.6M
Call Options Held
1.22M
Put Options Held
1.51M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email